Elutia (NASDAQ:ELUT - Get Free Report) will be announcing its earnings results after the market closes on Thursday, November 14th.
Elutia Price Performance
Shares of NASDAQ:ELUT remained flat at $3.80 on Tuesday. The stock had a trading volume of 6,535 shares, compared to its average volume of 42,179. The stock's 50 day simple moving average is $3.76 and its 200 day simple moving average is $3.67. Elutia has a fifty-two week low of $1.39 and a fifty-two week high of $5.24. The company has a market capitalization of $129.43 million, a PE ratio of -1.33 and a beta of 0.76.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $10.00 price objective on shares of Elutia in a report on Friday, September 6th.
Read Our Latest Stock Analysis on Elutia
About Elutia
(
Get Free Report)
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
Recommended Stories
Before you consider Elutia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elutia wasn't on the list.
While Elutia currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
